# Qlucore

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/qlucore).

## Overview

Qlucore is a Swedish software company that develops AI-based tools for precision medicine and genetic data analysis. Its portfolio includes Qlucore Omics Explorer for research and Qlucore Diagnostics for clinical use, with customers in healthcare, research, and life sciences across Europe and other international markets.

## Products & services

• Qlucore Omics Explorer for genetic data analysis
• Qlucore Diagnostics for clinical decision support
• CE-marked diagnostic tests for leukemia
• Qlucore Insights for cancer diagnostics
• AI-based precision medicine software

- **Research software** (65%) — Software for advanced analysis and visualization of genetic and omics data.
- **Clinical diagnostics** (25%) — Regulatory-approved software tests used to support cancer diagnosis in healthcare.
- **Diagnostic development projects** (10%) — New cancer diagnostic models and tests under development with partners and grants.

- Qlucore Omics Explorer for genetic data analysis
- Qlucore Diagnostics for clinical decision support
- CE-marked diagnostic tests for leukemia
- Qlucore Insights for cancer diagnostics
- AI-based precision medicine software

## Customers

Qlucore sells to hospitals, clinical laboratories, and healthcare providers that use its diagnostic software to classify patients and support treatment decisions. It also serves researchers and pharmaceutical companies that use Qlucore Omics Explorer for advanced genetic and biomarker analysis. In diagnostics, the company’s buyers are typically hospitals and healthcare systems that need CE-marked tools for regulated clinical use.

- **Hospitals and healthcare systems** (primary) — Buy diagnostic software for leukemia and other cancer applications to support clinical decision-making.
- **Research institutions** (primary) — Use Qlucore Omics Explorer for exploratory analysis of genetic and omics data.
- **Pharmaceutical companies** (secondary) — Use the research platform for biomarker discovery and patient stratification.
- **Clinical laboratories** (secondary) — Adopt CE-marked diagnostic tests for regulated use in healthcare settings.

- Hospitals using leukemia diagnostics for pediatric patients
- Clinical labs needing CE-marked diagnostic software
- Researchers analyzing genomic and omics datasets
- Pharmaceutical companies studying biomarkers and patient groups
- Healthcare providers evaluating cancer classification tools

## Geography

Qlucore is headquartered in Sweden and sells primarily into Europe, where CE-marking under IVDR is required for clinical diagnostics. Its reported customer base also extends to the United States, China, India, parts of South America, and the Middle East through direct sales and agents, reflecting a global research and diagnostics footprint.

- **Europe** (60%) — Core market for CE-marked diagnostics and research software
- **North America** (20%) — Includes U.S. research and healthcare demand
- **Asia** (10%) — Includes China agent-led sales and broader Asian demand
- **Rest of World** (10%) — Includes parts of South America and Middle East

- Sweden is the operating base and reporting currency is SEK
- Europe is the core market for CE-marked diagnostics
- United States is an important research and diagnostics market
- China is served through an agent for software products
- Middle East and other international markets add growth potential

## Strategy

Qlucore’s strategy is to expand from research software into regulated diagnostics by building a portfolio of CE-marked cancer tests. It is also broadening its product set across leukemia, lung, bladder, and AML while using distributors and agents to extend market reach beyond its direct sales base.

- **Build a broader diagnostics portfolio** (medium-term) — Multiple approved tests can increase clinical adoption and reduce dependence on one indication.
- **Expand commercial reach through partners** (short-term) — Agents and distributors help scale sales in markets where direct coverage is limited.
- **Protect the research software franchise** (short-term) — Omics Explorer remains the installed base and brand anchor for the company.

- Expand CE-marked diagnostics beyond the first leukemia test
- Develop lung, bladder, and AML diagnostic models
- Use distributors and agents to widen international reach
- Leverage reusable software and documentation across tests
- Maintain Qlucore Omics Explorer as the research platform base

## Risks

Qlucore depends on a small number of software products and on customer adoption in regulated healthcare markets, so demand can be uneven and sensitive to procurement cycles. Its business is also exposed to competition from free research tools, regulatory requirements for diagnostics, and funding conditions in academic and healthcare markets.

- **Multi-year license revenue timing** [high] — Revenue is recognized upfront for multi-year contracts, creating volatility between periods.
- **Competition from free/open-source tools** [medium] — Researchers may substitute lower-cost alternatives, reducing conversion and renewal rates.
- **Regulatory and clinical adoption risk** [high] — Diagnostics require CE marking and hospital acceptance before meaningful scale is achieved.
- **Dependence on research funding** [medium] — Cuts in academic or public research budgets can delay purchases and renewals.
- **Geopolitical and macroeconomic uncertainty** [medium] — International sales and customer budgets can be affected by weaker global conditions.

- Revenue can be lumpy because multi-year licenses are recognized upfront
- Free open-source tools can pressure research software demand
- Diagnostics depend on regulatory approval and healthcare adoption
- Customer spending can be delayed by weak research funding or budgets
- International expansion adds execution and partner risk

## Accounting

Qlucore’s reported revenue can fluctuate because multi-year software licenses are recognized in full when the contract is signed, rather than evenly over the service period. Investors should also watch the treatment of deferred tax assets, capitalized development costs, and any impairment risk tied to intangible assets and acquired technology.

- **Multi-year license revenue recognition** — Qlucore Omics Explorer and Qlucore Insights
- **Capitalized development costs** — Clinical test development programs
- **Deferred tax asset recognition** — Parent company tax deficit
- **Impairment of intangible assets** — Software and development assets

- Upfront revenue recognition for multi-year licenses can distort period comparability
- Development costs and grants affect the timing of expense recognition
- Deferred tax assets depend on future taxable profits
- Intangible asset impairment risk matters if product demand weakens
- Quarterly sales can be volatile because of small contract counts

---

*Last updated: 2026-08-11T04:04:55.417065+00:00*